The researchers published 2-year outcomes for the first three patients in July 2013. Results were described as promising. The Phase I/II clinical trial is complete. No additional patients are being recruited while the data is analyzed and work progresses to improve the manufacturability and repeatability of the technology while expansion to other geographies to increase access is being considered. Recruiting was completed for the 20 patient cohort in April 2015, which includes an expansion in December 2014 to add 6 additional patients. Inclusion criteria are pre-symptomatic late infantiles and both pre- and early-symptomatic juveniles. See details on inclusion criteria and the trial protocol here. The trial was at a single center at the San Raffaele Institute in Milan, Italy. All costs were to be paid by the researchers. This was a 3-year study. In March 2013, the last of the 8 primary trial patients started therapy. The trial had several compassionate access patients and ultimately was expanded to 20 patients
In late 2013 GSK exercised its option for the San Rafaelle gene therapy technology and is working with the Milan Investigators to prepare for the next phase of study. Intracerebral Gene therapy – A Phase I/II Clinical Trial started recruiting in Paris in late March, 2013 for an Intracerebral Gene Therapy clinical trial where special "vectors" carrying genetically modified material are directly injected into a dozen sites in the brain. The hope is that the corrected cells and the enzyme they produce will then diffuse into surrounding areas of the brain.
Intraocular hemorrhage is bleeding (hemorrhage) inside the eye (oculus in Latin) . It may be the result of physical trauma (direct injury to the eye) or other diseases, injuries or disorders (such as diabetes, hypertension, or shaken baby syndrome). Severe bleeding may cause high pressures inside the eye, leading to blindness. Types
The types of ocular hemorrhages are classified based on where the bleeding is occurring:

Subconjunctival hemorrhage (bleeding just underneath the conjunctiva)
Intraocular hemorrhages:
Hyphema (in the anterior chamber)
In the posterior segment of eyeball:
Vitreous hemorrhage (into the vitreous)
Subretinal hemorrhage (under the retina)
Submacular hemorrhage (under the macula)

Causes
Different causes may cause bleeding in different locations. Tersons syndrome (as a result of subarachnoid hemorrhage)
Hemophilia (a severe bleeding disorder, usually hereditary)
Anticoagulants and thrombolysis (medication to reduce blood clotting tendency or to disperse blood clots, respectively)The major causes of bleeding are injury diabetes mellitus hypertension. Diagnosis
Intraocular hemorrhage is typically diagnosed with slit lamp examination. Treatment
References


== External links ==